Despite the clear benefits demonstrated by immunotherapy, there is still an inevitable off-
target effect resulting in serious adverse immune reactions. In recent years, the research and …

Cancer is the most common cause of human death worldwide, posing a serious threat to
human health and having a negative impact on the economy. In the past few decades …

Antibody-drug conjugates (ADCs) are a growing class of chemotherapeutic agents for the
purpose of treating cancers that often have relapsed or failed first-and second-line …

The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in
cancer treatment has garnered significant attention. By combining the selective specificity of …

In the era of precision medicine, antibody-drug conjugates (ADCs) have emerged as a
cutting-edge therapeutic strategy. These innovative compounds combine the precision of …

Immune-stimulating antibody conjugates (ISACs) equipped with imidazoquinoline (IMD)
payloads can stimulate endogenous immune cells to kill cancer cells, ultimately inducing …

Immunostimulatory antibody conjugates (ISACs) as a promising new generation of targeted
therapeutic antibody-drug conjugates (ADCs), that not only activate innate immunity but also …

The 21st‐century beginning remarked with the huge success of monospecific MAbs,
however, in the last couple of years, polyspecific MAbs (PsAbs) have been an interesting …

Abstract Purpose of Review This study is to highlight the incidence of corneal
pseudomicrocysts in FDA-approved antibody–drug conjugates (ADCs), and success of …

We have previously demonstrated that Claudin-2 is required for colorectal cancer (CRC)
liver metastasis. The expression of Claudin-2 in primary CRC is associated with poor …